We are building a digital twin platform for lung diseases -a monolithic digital tool that will guide the actions of decision-makers in healthcare and life sciences through physics-based simulation, AI and data science. In the hands of industrial users, it enhances the understanding of pulmonary drug delivery, in order to inform, accelerate and reduce the risk in the planning and execution of studies.
In the hands of physicians, it will open up personalised treatment perspectives that will improve the survival and recovery of millions of cases of respiratory complications, starting with acute respiratory distress syndrome (ARDS) anywhere and anytime. Finally, in the hands of patients, it will serve to achieve their personalised therapy goals.
